Spero Therapeutics, Inc. SPRO · NASDAQ
$1.12 +1.82% (+$0.02)
Summary
72 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- It holds more cash than debt: $50.8M against $2.04M.
- You pay 8.8 USD for 1 USD of yearly profit, little for its sector.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- Revenue growth is slowing: 7.1% a year over the last 3 years against 45% over 5 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 8.8 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 45% a year over 5 years. Over the last 3 years it grew by 7.1% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 0.0 USD
- Research and development 48 USD
- Sales and administration 38 USD
- Taxes and other -3.2 USD
- Net profit 17 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 5
- Sell 2
No analyst has published a price target.
46% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenue Related Party 70%
- Collaboration Revenue 19%
- Grant Revenue 11%
By region
The company reports no revenue by region.
Collaboration Revenue Related Party brings in 70% of revenue.
Segments in detail